{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-041320","form_type":"8-K","ticker":"LONA","cik":"0001620463","company_name":"LeonaBio, Inc.","filed_at":"2023-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.586670+00:00","generated_at":"2026-06-11T17:45:10.075129+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Athira Pharma Q2 net loss $29.6M ($0.78/sh); cash $196.3M; LIFT-AD results H2 2024","bullets":["Net loss $29.6M ($0.78/sh) vs $24.3M ($0.65/sh) in Q2 2022; R&D spend rose to $21.6M.","Cash, cash equivalents and investments $196.3M at June 30, 2023, down from $245.2M at Dec 31, 2022.","Completed end-of-Phase 2 FDA meeting for fosgonimeton; LIFT-AD topline expected H2 2024.","Appointed Andrew Gengos as CFO and Chief Business Officer.","IND-enabling studies for ATH-1105 continue; first-in-human studies targeted H1 2024 for ALS."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-041320","json":"https://secwatch.observer/filing/0000950170-23-041320.json","markdown":"https://secwatch.observer/filing/0000950170-23-041320.md","text":"https://secwatch.observer/filing/0000950170-23-041320.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1620463/000095017023041320/0000950170-23-041320-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1620463/000095017023041320/atha-20230810.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T17:45:10.075129+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e2d343ff84bc5291dbe6aa63a7ac35ab604fee19","claim":"LeonaBio, Inc. reported financial results for quarter ended June 30, 2023.","evidence_excerpt":"On August 10, 2023, Athira Pharma, Inc. (the “Company”) issued a press release reporting its financial results for the quarter ended June 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1620463/000095017023041320/0000950170-23-041320-index.htm","confidence":0.92,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter ended June 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}